Avacta Group (AVCT)

 

AVCT Share PerformanceMore

52 week high98.00 26/05/17
52 week low60.00 31/03/17
52 week change -6.50 (-8.90%)
4 week volume295,899 25/12/17

Media for (AVCT)

Presenter: Dr. Alastair Smith
31/07/2014
Presenter: Dr. Alastair Smith
06/05/2014

Latest NewsMore

Avacta in line with market forecasts

Avacta expects revenue, operating losses and cash balances for the six months ending 31 Jan to be in line with market forec...

HardmanResearch: Affimer Drug Conjugates a reality

RNS Number: 8785B Avacta Group PLC 15 January 2018 Hardman Research: Affimer Drug Conjugates a reality Affimer Drug Conjugates a reality - Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which...

Avacta agrees development partnership with Glythera

Avacta Group and Glythera have agreed the terms of a licensing deal which will allow them to develop drug conjugates u...

Drug Development Partnership with Glythera

RNS Number: 7915B Avacta Group PLC 15 January 2018 15 January 2018 Avacta Group plc ("Avacta" or "the Group" or "the Company") Positive Outcome of Proof-of-Concept Study with Glythera and Follow on Drug Development Partnership Successful proof-of-concept study leads to Affimer drug conjugate development partnership Affimers shown to have key ...

Avacta to host capital markets day

Avacta Group will host a capital markets day for financial analysts and institutional investors at finnCap's offices, 60 New...

Capital Markets Day Notification

RNS Number: 7710A Avacta Group PLC 08 January 2018 8 January 2018 Avacta Group plc ("Avacta", "the Group" or "the Company") Capital Markets Day Notification Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, today announces that it will host a Capital Markets Day for financial analysts and institutional investors on W...

PDMR Dealing and Issue of Equity

RNS Number: 9751A Avacta Group PLC 04 January 2018 4 January 2018 Avacta Group plc ("Avacta", "the Group" or "the Company") Issue of Equity Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, announces that application has been made for 5,805 new ordinary shares of 10p each (the "New Ordinary Shares") to b...

Avacta CEO to present at Biotech Showcase

Avacta Group chief executive Dr Alastair Smith will be presenting at the annual Biotech Showcase which is being held in ...

Fundamental DataMore

EPS-6.86
Dividend yield0 %

Latest discussion posts More

  • Re: Shareholder Update

    Do you really see Avacta as being a #2 billion company?
    15-Dec-2017
    Proverbs 26 vs 5
  • bit of info

    albeit back in sept 17 - article by amrik Guest Commentary: Affinity and beyond--Assessing the alternatives to therapeutic ...
    13-Dec-2017
    mol42
  • Re: 3% shareholders 071217

    Current significant shareholders are as follows IP Group plc ? 24.79% Lombard Odier Asset Management ? 10.77% Aviva 9.60% Ruffer LLP ? 7.08% J O Hambro - 6.72% Baillie ...
    13-Dec-2017
    mol42

Users' HoldingsMore

Users who hold Avacta Group also hold..

Codes & Symbols

ISINGB00BYYW9G87
SymbolsAVCT, LSE:AVCT, AVCT.L, AVCT:LN, LON:AVCT, XLON:AVCT

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account